Who are OTX-101 0.09%'s main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): Tears Naturale II Ophthalmic Solution, NAABAK eyedrops, OZODROP, LiquiTears, SJP-0035 0.001%.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/otx-101-0-09.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-06-10 · How we verify

OTX-101 0.09% — Competitive Intelligence Brief

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

OTX-101 0.09% (OTX-101 0.09%) competitive landscape: 5 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: ophthalmic solution. Area: Ophthalmology.

phase 3 ophthalmic solution Ophthalmology Small molecule Live · refreshed every 30 min

Target snapshot

OTX-101 0.09% (OTX-101 0.09%) — Sun Pharmaceutical Industries Limited. OTX-101 is a topical ophthalmic solution used to treat dry eye disease.

Comparator set (5 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target
OTX-101 0.09% TARGET	OTX-101 0.09%	Sun Pharmaceutical Industries Limited	phase 3	ophthalmic solution
Tears Naturale II Ophthalmic Solution	Tears Naturale II Ophthalmic Solution	ORA, Inc.	marketed	Artificial tear / Lubricating ophthalmic solution
NAABAK eyedrops	NAABAK eyedrops	Laboratoires Thea	marketed	Ophthalmic solution	Ocular inflammation and discomfort
OZODROP	OZODROP	University of Molise	marketed	Ozone therapy / Ophthalmic solution
LiquiTears	LiquiTears	Chakshu Research, Inc.	marketed	Artificial tear / Lubricating ophthalmic solution
SJP-0035 0.001%	SJP-0035 0.001%	Senju Pharmaceutical Co., Ltd.	phase 3	Topical ophthalmic solution

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (ophthalmic solution class)

Sun Pharmaceutical Industries Limited · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). OTX-101 0.09% — Competitive Intelligence Brief. https://druglandscape.com/ci/otx-101-0-09. Accessed 2026-06-10.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing